PDS Biotech - PDSB Net earnings per share for the last four quarters

Official company branding of PDS Biotechnology Corp (PDSB)

PDS Biotechnology is developing partnerships with the NCI and global pharma behemoths to accelerate testing of antiviral and anti-tumor vaccines. Experienced management enjoys market confidence, skillfully preparing projects for the final phases of verification. The business relies on Versamune, which integrates clinics through strict research protocols. This chart of current share prices reflects an EPS of 30.30, confirming the company's status as a developer of immune drugs.

PDS Biotechnology Corporation (PDSB) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/14/2026

PDSB (PDS Biotechnology Corp): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart PDS Biotechnology|PDSB - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization PDS Biotech|PDSB - Total Company Value
- book value of equity indicators:
Accounting Value per Share PDS Biotechnology|PDSB - Company Book Value|Market Cap to Net Assets Ratio pdsbiotech.com|PDSB - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital PDS Biotechnology|PDSB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio PDS Biotechnology|PDSB - Company Debts|Debts to Book Value PDS Biotech|PDSB - Company Long-Term Liabilities|Short-Term Indebtedness PDS Biotechnology|Intermediate Liquidity Ratio pdsbiotech.com
- earnings and market multiples details:
PDSB - Net Profit|Expected Net Income PDS Biotechnology|PDSB - P/E Multiple|Projected Price to Earnings Ratio PDS Biotechnology|PDSB - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation PDS Biotech|PDSB - Operating profit EBITDA|Net earnings per share (EPS TTM) PDS Biotechnology|PDSB - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months pdsbiotech.com|PDSB - Net earnings per share growth this year|Expected net earnings per share growth next year PDS Biotechnology
- revenue and sales details:
PDSB - Company Revenue|Company Expected Revenue PDS Biotechnology|PDSB - P/S Multiple|Market Cap to Projected Revenue PDS Biotech
Initial company analysis:PDSB, PDS Biotechnology Corporation
Mass-produced product of PDS Biotechnology Corporation

PDS Biotechnology focuses on developing innovative anti-tumor vaccines, which dictates high capital intensity and specific profit patterns during the development stage. The annual percentage growth of EPS TTM reflects the rolling dynamics of net income per share over 12 months, allowing investors to assess the rate of change in profitability and avoid false extrapolations when analyzing the extremes of this chart.

Direct competitors

Earnings per share for the trailing year IBRX (immunitybio.com)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Arcus Bio|Net earnings per share for the last 12 months Zymeworks Biopharmaceuticals (ZYME)|Earnings per share for the last twelve months Tango Therapeutics (TNGX)|Net earnings per share for the last 12 months iovance.com IOVA|Immatics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc XNCR|CMPX - Earnings per share for the last twelve months|REPL (Replimune Inc.) - Earnings per share for the last 12 months|Lyell Immunopharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months innate-pharma.com (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics, Inc.)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings - Earnings per share for the trailing year|MAIA (MAIA Biotechnology) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) liminatuspharma.com|Earnings per share for the last twelve months LAVA Therapeutics N.V. (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Therapeutics Inc (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TOVX|GRTS: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months KA|Earnings per share for the last twelve months NexImmune Corp|Turnstone Biologics Corporation (TSBX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months VCNX (Vaccinex, Inc.)|HARP (harpoontx.com) - Earnings per share for the trailing year